Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 193 to 203 of 203 entries
Sorted by: Best Match Show Resources per page
Poststroke Bipolar Disorder.

The Journal of nervous and mental disease

Saraiva R, Proença F, Gonçalves M, Sereijo C, Barandas R, Coentre R, Levy P.
PMID: 34698700
J Nerv Ment Dis. 2021 Nov 01;209(11):851-854. doi: 10.1097/NMD.0000000000001410.

ABSTRACT: Various diseases that impact different systems and organs in the body may trigger manic episodes. Strokes are often associated with psychiatric symptoms, particularly depressive and, more rarely, manic. We herein report a case of bipolar disorder secondary to...

Cite
Saraiva R, Proença F, Gonçalves M, et al. Poststroke Bipolar Disorder. J Nerv Ment Dis. 2021;209(11):851-854doi: 10.1097/NMD.0000000000001410.
Saraiva, R., Proença, F., Gonçalves, M., Sereijo, C., Barandas, R., Coentre, R., & Levy, P. (2021). Poststroke Bipolar Disorder. The Journal of nervous and mental disease, 209(11), 851-854. https://doi.org/10.1097/NMD.0000000000001410
Saraiva, Rodrigo, et al. "Poststroke Bipolar Disorder." The Journal of nervous and mental disease vol. 209,11 (2021): 851-854. doi: https://doi.org/10.1097/NMD.0000000000001410
Saraiva R, Proença F, Gonçalves M, Sereijo C, Barandas R, Coentre R, Levy P. Poststroke Bipolar Disorder. J Nerv Ment Dis. 2021 Nov 01;209(11):851-854. doi: 10.1097/NMD.0000000000001410. PMID: 34698700.
Copy Download .nbib Format: NLM
[Primary Sjögren's syndrome: exocrine and non-exocrine manifestations].

Revista brasileira de reumatologia

Muñoz Mda G, Castelão WC, Saraiva FM, Costa JC, Queiroz MF.
PMID: 21503538
Rev Bras Reumatol. 2004 Apr;44(2):129-38. doi: 10.1590/s0482-50042004000200005.

OBJECTIVE: to characterize the exocrine and non-exocrine clinical disease manifestations of 74 patients with primary Sjögren's Syndrome (pSS).METHODS: retrospective study of pSS patients according to the new 2002 American-European criteria, followed in the Hospital Santa Maria, Rheumatology Outpatient Clinics,...

Cite
Muñoz Mda G, Castelão WC, Saraiva FM, et al. Síndrome de Sjögren primária: manifestações exócrinas e não exócrinas. [Primary Sjögren's syndrome: exocrine and non-exocrine manifestations]. Rev Bras Reumatol. 2004;44(2):129-38doi: 10.1590/s0482-50042004000200005.
Muñoz, M. d. a. . G., Castelão, W. C., Saraiva, F. M., Costa, J. C., & Queiroz, M. F. (2004). Síndrome de Sjögren primária: manifestações exócrinas e não exócrinas. [Primary Sjögren's syndrome: exocrine and non-exocrine manifestations]. Revista brasileira de reumatologia, 44(2), 129-38. https://doi.org/10.1590/s0482-50042004000200005
Muñoz, Maria da Graça Henriques da Conceição Negrão Sequeira, et al. "Síndrome de Sjögren primária: manifestações exócrinas e não exócrinas." [Primary Sjögren's syndrome: exocrine and non-exocrine manifestations]. Revista brasileira de reumatologia vol. 44,2 (2004): 129-38. doi: https://doi.org/10.1590/s0482-50042004000200005
Muñoz Mda G, Castelão WC, Saraiva FM, Costa JC, Queiroz MF. Síndrome de Sjögren primária: manifestações exócrinas e não exócrinas. [Primary Sjögren's syndrome: exocrine and non-exocrine manifestations]. Rev Bras Reumatol. 2004 Apr;44(2):129-38. doi: 10.1590/s0482-50042004000200005. Portuguese. PMID: 21503538.
Copy Download .nbib Format: NLM
Neurophysiological Changes in the First Year After Cell Transplantation in Sub-acute Complete Paraplegia.

Frontiers in neurology

Santamaria AJ, Benavides FD, Saraiva PM, Anderson KD, Khan A, Levi AD, Dietrich WD, Guest JD.
PMID: 33536992
Front Neurol. 2021 Jan 18;11:514181. doi: 10.3389/fneur.2020.514181. eCollection 2020.

Neurophysiological testing can provide quantitative information about motor, sensory, and autonomic system connectivity following spinal cord injury (SCI). The clinical examination may be insufficiently sensitive and specific to reveal evolving changes in neural circuits after severe injury. Neurophysiologic data...

Cite
Santamaria AJ, Benavides FD, Saraiva PM, et al. Neurophysiological Changes in the First Year After Cell Transplantation in Sub-acute Complete Paraplegia. Front Neurol. 2021;11:514181doi: 10.3389/fneur.2020.514181.
Santamaria, A. J., Benavides, F. D., Saraiva, P. M., Anderson, K. D., Khan, A., Levi, A. D., Dietrich, W. D., & Guest, J. D. (2020). Neurophysiological Changes in the First Year After Cell Transplantation in Sub-acute Complete Paraplegia. Frontiers in neurology, 11514181. https://doi.org/10.3389/fneur.2020.514181
Santamaria, Andrea J, et al. "Neurophysiological Changes in the First Year After Cell Transplantation in Sub-acute Complete Paraplegia." Frontiers in neurology vol. 11 (2020): 514181. doi: https://doi.org/10.3389/fneur.2020.514181
Santamaria AJ, Benavides FD, Saraiva PM, Anderson KD, Khan A, Levi AD, Dietrich WD, Guest JD. Neurophysiological Changes in the First Year After Cell Transplantation in Sub-acute Complete Paraplegia. Front Neurol. 2021 Jan 18;11:514181. doi: 10.3389/fneur.2020.514181. eCollection 2020. PMID: 33536992; PMCID: PMC7848788.
Copy Download .nbib Format: NLM
Cariprazine Use in Early Psychosis: Three Case Reports.

Frontiers in psychiatry

Coentre R, Saraiva R, Sereijo C, Levy P.
PMID: 34975583
Front Psychiatry. 2021 Dec 16;12:788281. doi: 10.3389/fpsyt.2021.788281. eCollection 2021.

No abstract available.

Cite
Coentre R, Saraiva R, Sereijo C, et al. Cariprazine Use in Early Psychosis: Three Case Reports. Front Psychiatry. 2021;12:788281doi: 10.3389/fpsyt.2021.788281.
Coentre, R., Saraiva, R., Sereijo, C., & Levy, P. (2021). Cariprazine Use in Early Psychosis: Three Case Reports. Frontiers in psychiatry, 12788281. https://doi.org/10.3389/fpsyt.2021.788281
Coentre, Ricardo, et al. "Cariprazine Use in Early Psychosis: Three Case Reports." Frontiers in psychiatry vol. 12 (2021): 788281. doi: https://doi.org/10.3389/fpsyt.2021.788281
Coentre R, Saraiva R, Sereijo C, Levy P. Cariprazine Use in Early Psychosis: Three Case Reports. Front Psychiatry. 2021 Dec 16;12:788281. doi: 10.3389/fpsyt.2021.788281. eCollection 2021. PMID: 34975583; PMCID: PMC8716595.
Copy Download .nbib Format: NLM
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer.

Pathobiology : journal of immunopathology, molecular and cellular biology

Dionísio de Sousa IJ, Cunha AI, Saraiva IA, Portugal RV, Gimba ERP, Guimarães M, Prazeres H, Lopes JM, Soares P, Lima RT.
PMID: 34689147
Pathobiology. 2021;88(6):400-411. doi: 10.1159/000517372. Epub 2021 Oct 22.

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is among the most active therapies for recurrent/progressive ovarian cancer (OC). Low-density lipoprotein receptor-related protein 1B (LRP1B) is one of the 10 most significantly deleted genes in human cancers. It mediates endocytosis of several...

Cite
Dionísio de Sousa IJ, Cunha AI, Saraiva IA, et al. LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology. 2021;88(6):400-411doi: 10.1159/000517372.
Dionísio de Sousa, I. J., Cunha, A. I., Saraiva, I. A., Portugal, R. V., Gimba, E. R. P., Guimarães, M., Prazeres, H., Lopes, J. M., Soares, P., & Lima, R. T. (2021). LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology, 88(6), 400-411. https://doi.org/10.1159/000517372
Dionísio de Sousa, Isabel J, et al. "LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer." Pathobiology : journal of immunopathology, molecular and cellular biology vol. 88,6 (2021): 400-411. doi: https://doi.org/10.1159/000517372
Dionísio de Sousa IJ, Cunha AI, Saraiva IA, Portugal RV, Gimba ERP, Guimarães M, Prazeres H, Lopes JM, Soares P, Lima RT. LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology. 2021;88(6):400-411. doi: 10.1159/000517372. Epub 2021 Oct 22. PMID: 34689147.
Copy Download .nbib Format: NLM
Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.

EClinicalMedicine

Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, Xavier SS, de Sousa AS, Costa AR, de Holanda MT, Veloso HH, Mendes FSNS, Costa FAC, Boia MN, Brasil PEAA, Carneiro FM, da Silva GMS, Mediano MFF.
PMID: 33554085
EClinicalMedicine. 2020 Dec 23;31:100694. doi: 10.1016/j.eclinm.2020.100694. eCollection 2021 Jan.

BACKGROUND: Chagas disease (CD) remains an important endemic disease in Latin America. However, CD became globalized in recent decades. The majority of the chronically infected individuals did not receive etiologic treatment for several reasons, among them the most conspicuous...

Cite
Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, et al. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. EClinicalMedicine. 2020;31:100694doi: 10.1016/j.eclinm.2020.100694.
Hasslocher-Moreno, A. M., Saraiva, R. M., Sangenis, L. H. C., Xavier, S. S., de Sousa, A. S., Costa, A. R., de Holanda, M. T., Veloso, H. H., Mendes, F. S. N. S., Costa, F. A. C., Boia, M. N., Brasil, P. E. A. A., Carneiro, F. M., da Silva, G. M. S., & Mediano, M. F. F. (2021). Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. EClinicalMedicine, 31100694. https://doi.org/10.1016/j.eclinm.2020.100694
Hasslocher-Moreno, Alejandro M, et al. "Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study." EClinicalMedicine vol. 31 (2021): 100694. doi: https://doi.org/10.1016/j.eclinm.2020.100694
Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, Xavier SS, de Sousa AS, Costa AR, de Holanda MT, Veloso HH, Mendes FSNS, Costa FAC, Boia MN, Brasil PEAA, Carneiro FM, da Silva GMS, Mediano MFF. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. EClinicalMedicine. 2020 Dec 23;31:100694. doi: 10.1016/j.eclinm.2020.100694. eCollection 2021 Jan. PMID: 33554085; PMCID: PMC7846661.
Copy Download .nbib Format: NLM
Antioxidant compounds from Annona crassiflora fruit peel reduce lipid levels and oxidative damage and maintain the glutathione defense in hepatic tissue of Triton WR-1339-induced hyperlipidemic mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Ramos LPA, Justino AB, Tavernelli N, Saraiva AL, Franco RR, de Souza AV, Silva HCG, de Moura FBR, Botelho FV, Espindola FS.
PMID: 34426250
Biomed Pharmacother. 2021 Oct;142:112049. doi: 10.1016/j.biopha.2021.112049. Epub 2021 Aug 23.

Dyslipidemia is a risk factor for the pathogenesis of several diseases, such as obesity, hypertension, atherosclerosis and cardiovascular diseases. In addition to interfering with serum concentrations of cholesterol and triglycerides, hyperlipidemia is involved in oxidative stress increase and reduction...

Cite
Ramos LPA, Justino AB, Tavernelli N, et al. Antioxidant compounds from Annona crassiflora fruit peel reduce lipid levels and oxidative damage and maintain the glutathione defense in hepatic tissue of Triton WR-1339-induced hyperlipidemic mice. Biomed Pharmacother. 2021;142:112049doi: 10.1016/j.biopha.2021.112049.
Ramos, L. P. A., Justino, A. B., Tavernelli, N., Saraiva, A. L., Franco, R. R., de Souza, A. V., Silva, H. C. G., de Moura, F. B. R., Botelho, F. V., & Espindola, F. S. (2021). Antioxidant compounds from Annona crassiflora fruit peel reduce lipid levels and oxidative damage and maintain the glutathione defense in hepatic tissue of Triton WR-1339-induced hyperlipidemic mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 142112049. https://doi.org/10.1016/j.biopha.2021.112049
Ramos, Letícia Pereira Afonso, et al. "Antioxidant compounds from Annona crassiflora fruit peel reduce lipid levels and oxidative damage and maintain the glutathione defense in hepatic tissue of Triton WR-1339-induced hyperlipidemic mice." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 142 (2021): 112049. doi: https://doi.org/10.1016/j.biopha.2021.112049
Ramos LPA, Justino AB, Tavernelli N, Saraiva AL, Franco RR, de Souza AV, Silva HCG, de Moura FBR, Botelho FV, Espindola FS. Antioxidant compounds from Annona crassiflora fruit peel reduce lipid levels and oxidative damage and maintain the glutathione defense in hepatic tissue of Triton WR-1339-induced hyperlipidemic mice. Biomed Pharmacother. 2021 Oct;142:112049. doi: 10.1016/j.biopha.2021.112049. Epub 2021 Aug 23. PMID: 34426250.
Copy Download .nbib Format: NLM
Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase.

Journal of ethnopharmacology

Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS.
PMID: 34890729
J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08.

ETHNOPHARMACOLOGICAL RELEVANCE: Different parts of Eugenia dysenterica have been popularly used in Brazil for treating diabetes mellitus and its complications. The present study aimed to screen extracts from E. dysenterica fruit pulp, peel, seed and leaf for carbohydrate digestive...

Cite
Justino AB, Guerra Silva HC, Franco RR, et al. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021;285:114902doi: 10.1016/j.jep.2021.114902.
Justino, A. B., Guerra Silva, H. C., Franco, R. R., de Oliveira Cavalcante Pimentel, I., Silva, N. F., Saraiva, A. L., & Espindola, F. S. (2021). Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. Journal of ethnopharmacology, 285114902. https://doi.org/10.1016/j.jep.2021.114902
Justino, Allisson Benatti, et al. "Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase." Journal of ethnopharmacology vol. 285 (2021): 114902. doi: https://doi.org/10.1016/j.jep.2021.114902
Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08. PMID: 34890729.
Copy Download .nbib Format: NLM
Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase.

Journal of ethnopharmacology

Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS.
PMID: 34890729
J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08.

ETHNOPHARMACOLOGICAL RELEVANCE: Different parts of Eugenia dysenterica have been popularly used in Brazil for treating diabetes mellitus and its complications. The present study aimed to screen extracts from E. dysenterica fruit pulp, peel, seed and leaf for carbohydrate digestive...

Cite
Justino AB, Guerra Silva HC, Franco RR, et al. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021;285:114902doi: 10.1016/j.jep.2021.114902.
Justino, A. B., Guerra Silva, H. C., Franco, R. R., de Oliveira Cavalcante Pimentel, I., Silva, N. F., Saraiva, A. L., & Espindola, F. S. (2021). Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. Journal of ethnopharmacology, 285114902. https://doi.org/10.1016/j.jep.2021.114902
Justino, Allisson Benatti, et al. "Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase." Journal of ethnopharmacology vol. 285 (2021): 114902. doi: https://doi.org/10.1016/j.jep.2021.114902
Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08. PMID: 34890729.
Copy Download .nbib Format: NLM
Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem.

Pharmaceutics

Masoumi F, Saraiva SM, Bouzo BL, López-López R, Esteller M, Díaz-Lagares Á, de la Fuente M.
PMID: 34575588
Pharmaceutics. 2021 Sep 18;13(9). doi: 10.3390/pharmaceutics13091507.

Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor...

Cite
Masoumi F, Saraiva SM, Bouzo BL, et al. Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem. Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091507.
Masoumi, F., Saraiva, S. M., Bouzo, B. L., López-López, R., Esteller, M., Díaz-Lagares, �. �., & de la Fuente, M. (2021). Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem. Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091507
Masoumi, Farimah, et al. "Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091507
Masoumi F, Saraiva SM, Bouzo BL, López-López R, Esteller M, Díaz-Lagares Á, de la Fuente M. Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem. Pharmaceutics. 2021 Sep 18;13(9). doi: 10.3390/pharmaceutics13091507. PMID: 34575588; PMCID: PMC8470159.
Copy Download .nbib Format: NLM
Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase.

Journal of ethnopharmacology

Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS.
PMID: 34890729
J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08.

ETHNOPHARMACOLOGICAL RELEVANCE: Different parts of Eugenia dysenterica have been popularly used in Brazil for treating diabetes mellitus and its complications. The present study aimed to screen extracts from E. dysenterica fruit pulp, peel, seed and leaf for carbohydrate digestive...

Cite
Justino AB, Guerra Silva HC, Franco RR, et al. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021;285:114902doi: 10.1016/j.jep.2021.114902.
Justino, A. B., Guerra Silva, H. C., Franco, R. R., de Oliveira Cavalcante Pimentel, I., Silva, N. F., Saraiva, A. L., & Espindola, F. S. (2021). Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. Journal of ethnopharmacology, 285114902. https://doi.org/10.1016/j.jep.2021.114902
Justino, Allisson Benatti, et al. "Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase." Journal of ethnopharmacology vol. 285 (2021): 114902. doi: https://doi.org/10.1016/j.jep.2021.114902
Justino AB, Guerra Silva HC, Franco RR, de Oliveira Cavalcante Pimentel I, Silva NF, Saraiva AL, Espindola FS. Flavonoids and proanthocyanidins-rich fractions from Eugenia dysenterica fruits and leaves inhibit the formation of advanced glycation end-products and the activities of α-amylase and α-glucosidase. J Ethnopharmacol. 2021 Dec 08;285:114902. doi: 10.1016/j.jep.2021.114902. Epub 2021 Dec 08. PMID: 34890729.
Copy Download .nbib Format: NLM
Showing 193 to 203 of 203 entries